For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Cyclerion Therapeutics, Inc.

USPTO Granted Patents = 24

CIPO Patents = 1

EPO Patents = 14

Trademarks = 4

Forward Citations = 28

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Takashi Nakai (11 out of 23 patents)

Song Xue (10 out of 12 patents)

Rajesh R Iyengar (10 out of 26 patents)

4. Paul A Renhowe (10 out of 59 patents)

5. Thomas Wai-Ho Lee (9 out of 17 patents)

6. Glen Robert Rennie (9 out of 32 patents)

7. Joon Jung (9 out of 23 patents)

8. Timothy Claude Barden (9 out of 18 patents)

9. Vishnu Vardhan Reddy Karnati (8 out of 8 patents)

10. G-Yoon Jamie Im (7 out of 13 patents)

11. Ara Mermerian (7 out of 18 patents)

12. James Edward Sheppeck (6 out of 27 patents)

13. Robert C Livingston (6 out of 7 patents)

14. Wayne C Schairer (6 out of 6 patents)

15. Ahmad Hashash (6 out of 8 patents)

24 patents: Sort by Forward Citations

1. 12275724 - Processes and intermediates for the preparation of soluble guanylate cyclase stimulators (2025-04-14),

2. 12247025 - Processes for preparation of soluble guanylate cyclase stimulators (2025-03-11),

3. 12030874 - Processes and intermediates for the preparation of soluble guanylate cyclase stimulators (2024-07-09),

4. 11834444 - Processes for preparation of soluble guanylate cyclase stimulators (2023-12-05),

5. 11773089 - Process for preparation of soluble guanylate cyclase stimulators (2023-10-03),

6. 11731977 - SGC stimulators (2023-08-22),

7. 11708361 - Processes and intermediates for the preparation of soluble guanylate cyclase stimulators (2023-07-25),

8. 11690828 - Treatment of CNS diseases with sGC stimulators (2023-07-04),

9. 11572358 - Solid forms of an sGC stimulator (2023-02-07),

10. 11466015 - Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators (2022-10-11),

11. 11466014 - Process for preparing soluble guanylate cyclase stimulators (2022-10-11),

12. 11389449 - Treatment of metabolic syndrome with an sGC stimulator (2022-07-19),

13. 11357777 - Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) (2022-06-14),

14. 11319308 - Processes for preparation of soluble guanylate cyclase stimulators (2022-05-03),

15. 11274096 - Processes and intermediates for the preparation of soluble guanylate cyclase stimulators (2022-03-15),

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing breakthrough treatments for serious and orphan diseases. They focus on addressing the underlying causes of diseases by targeting soluble guanylate cyclase (sGC), a key enzyme involved in several physiological processes. Working with a deep understanding of sGC pharmacology, they aim to deliver innovative therapies that have the potential to improve the lives of patients with unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

24 Patents

#95 in Cambridge, MA

#800 in Massachusetts

#13,428 in US

#25,864 in the World

Cambridge, MA, United States of America

Cyclerion Therapeutics, Inc.

Forward Citations = 28

41 inventors:

Takashi Nakai (11 out of 23 patents)

Song Xue (10 out of 12 patents)

Rajesh R Iyengar (10 out of 26 patents)

4. Paul A Renhowe (10 out of 59 patents)

5. Thomas Wai-Ho Lee (9 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…